Table 1.
Characteristics | CoronaVac | BNT162b2 | Unvaccinated |
---|---|---|---|
(N = 44) | (N = 47) | (N = 454) | |
Age, years (mean (SD)) | 58.89 (11.61) | 61.49 (15.30) | 70.48 (16.15) |
Sex, male (%) | 19 (43.2) | 26 (55.3) | 205 (45.2) |
Smoking (%) | 0 (0.0) | 0 (0.0) | 8 (1.8) |
Charlson Comorbidity Index (mean (SD)) | 1.80 (1.15) | 2.19 (1.57) | 3.87 (2.24) |
Diabetes (%) | 5 (11.4) | 3 (6.4) | 96 (21.1) |
Hypertension (%) | 4 (9.1) | 14 (29.8) | 177 (39.0) |
Asthma (%) | 0 (0.0) | 1 (2.1) | 7 (1.5) |
Neoplasms (%) | 0 (0.0) | 1 (2.1) | 74 (16.3) |
Acute respiratory infections (%) | 0 (0.0) | 2 (4.3) | 81 (17.8) |
Viral infections (%) | 0 (0.0) | 0 (0.0) | 2 (0.4) |
Rheumatoid Arthritis (%) | 1 (2.3) | 1 (2.1) | 16 (3.5) |
Stroke or systemic embolism (%) | 0 (0.0) | 0 (0.0) | 15 (3.3) |
Guillain–Barré syndrome (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Migraine (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Antiviral drugs (%) | 1 (2.3) | 3 (6.4) | 41 (9.0) |
Systemic corticosteroids (%) | 1 (2.3) | 5 (10.6) | 58 (12.8) |
Antibacterial drugs (%) | 1 (2.3) | 4 (8.5) | 106 (23.3) |
Immuno-suppressants (%) | 1 (2.3) | 5 (10.6) | 43 (9.5) |
Lipid lowering agents (%) | 11 (25.0) | 13 (27.7) | 180 (39.6) |
SD=Standard deviation